Third, although we have performed comprehensive genomic characterization of EGFR-mutant squamous cell lung cancer and try to figure out why EGFR-mutant SCC confers poor responsiveness to TKI in terms of mutation profiles, the underlying mechanisms have not been verified in vitro and in vivo. The gene discussed is EGFR; the disease is squamous cell lung carcinoma.